Antiviral Drugs : From Basic Discovery Through Clinical Trials
(Visualizza in formato marc)
(Visualizza in BIBFRAME)
| Autore: |
Kazmierski Wieslaw M
|
| Titolo: |
Antiviral Drugs : From Basic Discovery Through Clinical Trials
|
| Pubblicazione: | Hoboken, : Wiley, 2011 |
| Edizione: | 1st ed. |
| Descrizione fisica: | 1 online resource (470 p.) |
| Disciplina: | 615/.7924 |
| Soggetto topico: | Antiviral Agents -- therapeutic use |
| Antiviral agents | |
| Clinical Trials as Topic | |
| Drug Discovery | |
| Drug Evaluation | |
| Epidemiologic Studies | |
| Chemistry, Pharmaceutical | |
| Evaluation Studies as Topic | |
| Investigative Techniques | |
| Anti-Infective Agents | |
| Epidemiologic Methods | |
| Pharmacology | |
| Therapeutic Uses | |
| Health Care Evaluation Mechanisms | |
| Chemistry | |
| Biological Science Disciplines | |
| Natural Science Disciplines | |
| Quality of Health Care | |
| Public Health | |
| Pharmacologic Actions | |
| Environment and Public Health | |
| Health Care Quality, Access, and Evaluation | |
| Chemical Actions and Uses | |
| Delivery of Health Care | |
| Antiviral Agents | |
| Health & Biological Sciences | |
| Pharmacy, Therapeutics, & Pharmacology | |
| Persona (resp. second.): | KazmierskiWieslaw M. |
| Note generali: | Description based upon print version of record. |
| Nota di contenuto: | ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients |
| 7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir | |
| 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection | |
| 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir | |
| 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate | |
| Sommario/riassunto: | This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense so |
| Titolo autorizzato: | Antiviral Drugs |
| ISBN: | 1-283-20363-4 |
| 9786613203632 | |
| 0-470-92935-9 | |
| 0-470-92934-0 | |
| Formato: | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione: | Inglese |
| Record Nr.: | 9910808713803321 |
| Lo trovi qui: | Univ. Federico II |
| Opac: | Controlla la disponibilità qui |